WeVote
Log In

Bill

Bill

S 1799

A bill to amend title XVIII of the Social Security Act to provide for certain cognitive impairment detection in the Medicare annual wellness visit and initial preventative physical examination.

119th Congress Introduced by Richard Blumenthal and 2 co-sponsors

Requires cognitive impairment screening during Medicare AWV and IPPE to enable earlier diagnosis and care planning for beneficiaries and caregivers.

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 1799

Summary of S. 1799 (introduced May 19, 2025)

Purpose and intent

S. 1799 seeks to amend title XVIII of the Social Security Act to require cognitive impairment detection as part of the Medicare Annual Wellness Visit (AWV) and the Initial Preventive Physical Examination (IPPE). The bill is framed as a measure to improve early identification of Alzheimer’s disease and other dementias, enabling timely care planning, treatment options, and caregiver support.

Key provisions (as introduced)

  • Amends Medicare law (Title XVIII) to provide for cognitive impairment detection during the AWV and the IPPE for Medicare beneficiaries.
  • The underlying rationale emphasizes that early, documented diagnosis promotes care planning, access to medical and nonmedical treatments, and the formation of a care team, potentially improving outcomes for patients and reducing downstream burdens.

Note: The specific screening tools, reporting requirements, or timelines for implementing the cognitive impairment detection are not detailed in the summary text provided. The emphasis is on integrating detection into the AWV and IPPE.

Findings and context (fact pattern the bill cites)

The bill contains extensive findings about Alzheimer’s disease and related dementias, including:
- Prevalence and growth: estimated 6.9 million Americans with Alzheimer’s now, projected to nearly 13.8 million by 2060; about 1 in 11 people age 65+ has Alzheimer’s.
- Disparities: older Black Americans (2x) and Latino Americans (1.5x) more likely to have Alzheimer’s than older White Americans; roughly two-thirds of affected individuals are women.
- Burden and mortality: Alzheimer’s is a leading cause of death among 65+; deaths from dementia have risen significantly in recent decades.
- Economic impact: enormous costs from unpaid caregiving (approx. $347 billion in 2023), direct costs of dementia care (about $360 billion in 2024), with projected costs approaching $1.1 trillion by 2050; Medicare/Medicaid are expected to cover a substantial share of these costs, with substantial out-of-pocket spending as well.
- Potential for risk reduction: modifiable factors (hypertension, inactivity, smoking, depression, diabetes, obesity, nutrition) could prevent or delay up to ~40% of dementia cases.
- Benefits of early diagnosis: enables early access to care planning, treatments, support services, and trial enrollment; reduces caregiver burden and its health consequences.

Who is affected

  • Medicare beneficiaries undergoing AWV or IPPE (the primary scope of the requirement).
  • Healthcare providers and clinicians who administer AWV and IPPE services under Medicare.
  • Caregivers and families, who stand to gain from earlier diagnosis and care coordination.

Procedural and timeline aspects

  • Status: Introduced in the Senate on May 19, 2025.
  • Legislative actions: Read twice and referred to the Senate Committee on Finance (same date: May 19, 2025).
  • Sponsors: Primary sponsor Shelley Moore Capito; cosponsor Mark R. Warner.
  • Related bill: Companion bill HR 3501 (House of Representatives).

Potential impact

  • Health outcomes: earlier detection may improve management and access to treatments and support.
  • Economic: could influence Medicare utilization, long-term care planning, and caregiver costs; precise fiscal implications depend on implementation details (tools required, follow-up care, and reimbursement changes), which are not specified in the introduced text.
  • Equity considerations: highlighting disparities may drive targeted outreach and screening in higher-risk populations.

This summary reflects the introduced text and accompanying findings; further amendments or committee reports could refine provisions, tools, and implementation timelines.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.